| Revenue growth | +25.83% YoY to ₹55.04 Cr (H1 FY27) |
|---|---|
| Margins | EBITDA margin 22.48% vs 16.42%; PAT margin 14.90% vs 10.87% |
| Demand visibility | Sustained demand across key categories cited |
Growth
Revenue +25.83% YoY to ₹55.04 Cr; EBITDA +72.28% to ₹12.37 Cr; PAT +72.63% to ₹8.20 Cr.
Outlook
No numerical guidance given. Capex: leasing adjacent land and new machinery for capacity expansion; amount undisclosed.
Risks
No explicit risks or headwinds disclosed in the presentation.
Investor Presentation filed with NSE, NSE: ACCPL. Summary written with AI assistance from the document.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹212.00
- Market cap
- ₹235.7 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 24.4×Sector 42.0×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.